Table 3.
Comparison between PDAC and control groups regarding CD163 staining
| PDAC | Control | Test of Sig. | p | |
|---|---|---|---|---|
| H- score | ||||
| Min. – Max. | 0–270 | 0–160 |
Z = 7.843* |
< 0.001* |
| Mean ± SD. | 91.6 ± 56.1 | 15.10 ± 25.54 | ||
| Median (IQR) | 100 (40–120) | 0 (0–30) | ||
| Intensity | ||||
| Negative | 7 (7.1%) | 61 (62.2%) |
MH = 89.500* |
< 0.001* |
| Mild | 37 (37.8%) | 35 (35.7%) | ||
| Moderate | 45 (45.9%) | 2 (2%) | ||
| Strong | 9 (9.2%) | 0 (0%) | ||
| Percentage | ||||
| Min. – Max. | 0–100 | 0–90 |
Z = 7.645* |
< 0.001* |
| Mean ± SD. | 52.24 ± 224 | 13.88 ± 20.99 | ||
| Median (IQR) | 60 (40–60) | 0 (0–30) | ||
SD: Standard deviation Z: Wilcoxon signed ranks test
MH: Marginal Homogeneity Test
p: p value for comparing between tumor and control
*: Statistically significant at p ≤ 0.05